Get the Stockscreener App
5.02
3.93%
0.19
After Hours:
5.00
-0.02
-0.40%
Polypid Ltd stock is traded at $5.02, with a volume of 198.53K.
It is up +3.93% in the last 24 hours and up +6.58% over the past month.
PolyPid Ltd is a clinical-stage biopharmaceutical company engaged in the research and development of products based on PLEX (Polymer-Lipid Encapsulation MatriX), the company's proprietary drug delivery technology. PLEX is capable of encapsulating many types of drugs to enable targeted, localized drug delivery into the body over extended periods of time with pre-determined release rates thus optimizing drug treatment regimens. BonyPid, PolyPid, Opzifend, Ssisurg, Elyfssi, Baczenssi, Opzifend and Bacyssio are trademarks of the company. The company's product candidate include D-PLEX100 for prevention of SSI in soft tissue and OncoPLEX which can be a potential Intra-tumoral therapy.
See More
Previous Close:
$4.83
Open:
$4.83
24h Volume:
198.53K
Relative Volume:
3.03
Market Cap:
$96.25M
Revenue:
-
Net Income/Loss:
$-33.63M
P/E Ratio:
-2.625
EPS:
-1.9124
Net Cash Flow:
$-47.63M
1W Performance:
+12.56%
1M Performance:
+6.58%
6M Performance:
+39.44%
1Y Performance:
+79.93%
1-Day Range:
$4.83
$5.10
1-Week Range:
$4.56
$5.10
52-Week Range:
$2.44
$5.12
Polypid Ltd Stock (PYPD) Company Profile
Compare PYPD vs VRTX, REGN, ARGX, ALNY, RVMD
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
PYPD
Polypid Ltd
|
5.02 | 92.61M | 0 | -33.63M | -47.63M | -1.9124 |
VRTX
Vertex Pharmaceuticals Inc
|
434.52 | 110.03B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
638.88 | 67.37B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
806.46 | 50.76B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
297.45 | 40.12B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
151.56 | 32.68B | 742.00K | -1.37B | -1.07B | -7.0731 |
Polypid Ltd Stock (PYPD) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jun-05-25 | Initiated | Roth Capital | Buy |
| Jun-02-25 | Resumed | H.C. Wainwright | Buy |
| Jan-28-25 | Initiated | Rodman & Renshaw | Buy |
| Sep-14-21 | Initiated | JMP Securities | Mkt Outperform |
| Jul-30-21 | Initiated | Cantor Fitzgerald | Overweight |
| Nov-24-20 | Upgrade | Raymond James | Outperform → Strong Buy |
| Aug-10-20 | Initiated | Alliance Global Partners | Buy |
| Jul-21-20 | Initiated | BMO Capital Markets | Outperform |
| Jul-21-20 | Initiated | Barclays | Overweight |
| Jul-21-20 | Initiated | Raymond James | Outperform |
View All
Polypid Ltd Stock (PYPD) Latest News
PolyPid Q1 earnings call highlights - MSN
PolyPid (PYPD) Jumps 3.93% as Stock Approaches Key Resistance LevelSupport Level Bounce - Newser
PolyPid to Participate in the Craig-Hallum 23rd Annual Institutional Investor Conference - Yahoo Finance
PolyPid’s Earnings Call Signals Tightrope to Approval - TipRanks
PolyPid Ltd stock (US70450B1035): pivotal Phase 3 data and Nasdaq listing shift in focus - AD HOC NEWS
PolyPid Submits D-PLEX100 New Drug Application to FDA - HarianBasis.co
PolyPid Ltd.Ordinary Shares (NQ: PYPD - FinancialContent
PolyPid stock (US70450B1035): NDA submission advances D-PLEX100 toward FDA review - AD HOC NEWS
PolyPid Ltd. (NASDAQ:PYPD) Q1 2026 Earnings Call Transcript - Insider Monkey
PYPD Earning Date, Earning Analysis and Earning Prediction - Intellectia AI
PolyPid Earnings Call: NDA Momentum Amid Cash Strain - TipRanks
PolyPid Q1 Earnings Call Highlights - sharewise.com
PolyPid Ltd. Q1 2026 Earnings Call Summary - Yahoo Finance
PolyPid Q1 2026 Earnings Call Transcript - MarketBeat
PYPD: NDA submission for D-PLEX100 nears completion as financials improve and commercialization advances - TradingView
PolyPid Ltd reports results for the quarter ended December 31Earnings Summary - TradingView
PolyPid Q1 2026 Earnings Call: Complete Transcript - Benzinga
[6-K] PolyPid Ltd. Current Report (Foreign Issuer) | PYPD SEC FilingForm 6-K - Stock Titan
PolyPid Provides Corporate Update and Reports First Quarter 2026 Financial Results - marketscreener.com
PolyPid Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2026 - marketscreener.com
PolyPid Ltd (PYPD) Q1 2026 Earnings Call Highlights: Strategic Advances Amid Financial Challenges By GuruFocus - Investing.com Canada
Rosalind Advisors/Fund report 9.9% in PolyPid (PYPD) via warrants and shares - Stock Titan
TradingKey - TradingKey
PolyPid Ltd expected to post a loss of 43 cents a shareEarnings Preview - TradingView
Number of shareholders of PolyPid Ltd. – NASDAQ:PYPD - TradingView
How sustainable is PolyPid (PYPD) profit margins? (Smart Money Exits) 2026-05-08Street Ratings - newser.com
PolyPid (PYPD.US) will release its earnings report before the market opens on May 13. - Moomoo
PolyPid to Announce First Quarter 2026 Financial Results on May 13 and Host Conference Call at 8:30 AM ET - geneonline.com
PolyPid to Report First Quarter 2026 Financial Results and Operational Highlights on May 13, 2026 - The Manila Times
Aurum holds 5,001,561 shares in Polypid Ltd. (PYPD) with exercisable warrants - Stock Titan
AIGH Capital Management LLC Has $5.83 Million Stock Position in PolyPid Ltd. $PYPD - MarketBeat
PolyPid to Present Data from SHIELD II Phase 3 Trial Demonstrating Reduced Severity of Surgical Site Infection at Surgical Infection Society 2026 Annual Meeting - BioSpace
PolyPid to present wound infection data at surgery conference By Investing.com - Investing.com South Africa
PolyPid to present wound infection data at surgery conference - Investing.com
PolyPid to Present Data from SHIELD II Phase 3 Trial - GlobeNewswire
PYPD Price Today: PolyPid Ltd. Stock Price, Quote & Chart | MEXC - MEXC Exchange
Short Interest in PolyPid Ltd. (NASDAQ:PYPD) Increases By 166.1% - MarketBeat
PYPD (PolyPid Ltd. Ordinary Shares) reports wider than expected Q4 2025 loss, yet shares rise modestly in today’s trading.Pro Trader Recommendations - Cổng thông tin điện tử tỉnh Tây Ninh
PolyPid (PYPD) Stock Outlook | Q4 2025: Earnings UnderperformHigh Growth - Cổng thông tin điện tử tỉnh Lào Cai
PolyPid Ltd stock (US70450B1035): Is its drug-delivery tech strong enough to unlock biotech upside? - AD HOC NEWS
PolyPid Ltd stock (US70450B1035): Is its drug delivery tech strong enough to unlock surgical market - AD HOC NEWS
Nir Dror Darwish Net Worth (2026) - GuruFocus
Itzhak Krinsky Net Worth (2026) - GuruFocus
PolyPid (PYPD) Stock Recovery Underway (-1.27%) 2026-04-16Hot Momentum Watchlist - Cổng thông tin điện tử tỉnh Lào Cai
Yechezkel Barenholz Net Worth (2026) - GuruFocus
Dikla Czaczkes Akselbrad Net Worth (2026) - GuruFocus
Jonathan Missulawin Net Worth (2026) - GuruFocus
Yitzchak Shlomo Jacobovitz Net Worth (2026) - GuruFocus
PolyPid To Present Phase 3 SHIELD II Data Showing Sustained Local Doxycycline Release And Minimal Systemic Exposure At ESCMID 2026 Conference - Sahm
Roth MKM Maintains PolyPid(PYPD.US) With Buy Rating, Maintains Target Price $9 - Moomoo
PolyPid to present D-PLEX100 pharmacokinetic data at ESCMID Global By Investing.com - Investing.com Australia
Polypid Ltd Stock (PYPD) Financials Data
Revenue
Net Income
Cash Flow
EPS
2.98%
1.33%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):